Chimeric IL-10

Details Chimeric IL-10 Chimeric IL-10

2006-03-28

2006-03-28

Mertz, Prema (Department: 1646)

Drug, bio-affecting and body treating compositions

Lymphokine

Interleukin

C530S351000, C530S402000, C514S002600, C514S008100, C514S012200

Reexamination Certificate

active

07018626

ABSTRACT:
Disclosed are chimeric proteins having a cytokine fused to an enzymatically inactive polypeptide which increases the circulating half-life of the cytokine. The chimeric proteins are useful for treating, inhibiting, or preventing a variety of conditions, including septic shock, granulomatous disorders, Type I diabetes, and various cancers (e.g., multiple myeloma) in a patient.

REFERENCES:
patent: 5116964 (1992-05-01), Capon et al.
patent: 5196321 (1993-03-01), Bachmair et al.
patent: 5231012 (1993-07-01), Mosmann et al.
patent: 2045869 (1991-06-01), None
patent: 04 64 533 (1992-01-01), None
patent: 2686899 (1992-01-01), None
patent: WO 90 07932 (1990-07-01), None
patent: WO 94 04180 (1994-03-01), None
patent: WO94/08606 (1994-04-01), None
Laurence, D.R., “A Dictionary of Pharmacology and Allied Topics,” p. 90 (1998).
Rabinovitch, A., “Immunoregulatory and Cytokine Imbalances in the Pathogenesis of IDDM,” Diabetes, 43:613-621 (1994).
Steele, Alan W., et al.Structure and function in vitro and in vivo of a family of murine interleukin-2Fc... J. American Soc. Of Nephr. 4(3):636, 1993.
A. Traub, et al.Inerferon albumin conjugate with conserved biological activity, J. of General Virology 53:389-392, 1981.
Rene de Waal Malefyt, et al.Interleukin 10 (IL-10) and Viral IL-10 Strongly Reduce Antigen-specific Human T Cell Proliferation by Diminishing the Antigen... J. Exp. Med. 174:915-924, Oct., 1991.
Karl Byrne, et al.Adult Respiratory Distress Syndrome. Acute Care 13:206-234, 1987.
Roger C. Bone, M.D.The Pathogenesis of Sepsis. Annals of Internal Medicine, 115(6):457-469, Sep. 1991.
Catherine Gerard, et al.Interleukin 10 Reduces the Release of Tumor Necrosis Factor and Prevents Lethality in Experimental Endotoxemia. Journal of Experimental Medicine , 177(2):547-550, Feb. 1993.
David F. Fiorentino, et al.IL-10 Acts on the Antigen-Presenting Cell to Inhibit Cytokine Production by Th1 Cells. Journal of Immunology 146(10):3444-3451, May 1991.
David F. Fiorentino, et al.IL-10 Inhibits Cytokine Production by Activated Macrophages. Journal of Immunology 147(11):3815-3822, Dec. 1991.
Di-Hwei Hsu, et al.Differential effects of IL-4 and IL-10 on IL-2-induced IFN-γ synthesis and lymphokine-activated killer activity. International Immunology 4(5):563-569, 1992.
Myung-Shik Lee, et al.Pancreatic Islet Production of Murine Interleukin-10 Does Not Inhibit Immune-mediated Tissue Destruction. Journal of Clinical Investigation 93:1332-1338, 1994.
Kevin W. Moore, et al.Homology of Cytokine Synthesis Inhibitory Factor (IL-10) to the Epstein-Barr Virus bene BCRFI. Science 248:1230-1234, Jun. 1990.
Kevin W. Moore, et al.Interleukin-10. Annual Review of Immunology 11:165-190, 1993.
LuAnn Thompson-Snipes, et al.Interleukin-10: A Novel Stimulatory Factor for Mast Cells and Their Progenitors. Journal of Experimental Medicine 173(2):507-510, Feb. 1991.
Daniel J. Capon, et al.Designing CD4 immunoadhesins for Aids therapy. Nature 337:525-531, Feb. 1989.
1995 Cytokine Research Products Catalog, Genzyme Diagnostics; Cambridge, MA (Portions thereof.).
R. Doug Wagner, et al.Treatment with Anti-Interleukin-10 Monoclonal Antibody Enhances Early Resistance to but Impairs Complete Clearance of Listeria monocytogenes Infection in Mice, Infection and Immunity 62(6):2345-2353, Jun. 1994.
Kenneth J. Pennlike, et al.Recombinant Human IL-10 Prevents the Onset of Diabetes in the Nonobese Diabetic Mouse. Clinical Immunology and Immunopathology 71(2): 169-175, May 1994.
Nicholas F. Landolfi, et al.A Chimeric IL-2/l1 Molecule Possesses the Functional Activity of Both Proteins. Journal of Immunology 146(3):915-919, Feb. 1991.
Alexander R. Duncan, et al.The binding site for Clq and IgGNature 332:738-740, Apr. 1988.
Alexander R. Duncan, et al.Localization of the binding site for the human high-affinity Fc receptor, on IgG. Nature 332:563-564, Apr. 1988.
Xin Xiao Zheng, et al.Administration of Noncytolytic IL-10/Fx in Murine Models of Lipopolysaccharide-Induced Septic Shock and Allogenic Islet Transplantation. Journal of Immunology 154:5590-5600,1995.
Pedro O. Flores Villanueva, et al.Role of IL-10 on Antigen-Presenting Cell Function for Schistosomal Egg-Specific Monoclonal T Helper Cell Responses in Vitro and in Vivo. Journal of Immunology 151(6):3192-3198, Sep. 1993.
Summons to Attend Oral Proceedings Pursuant to Rule 71(1) EPC for Application European Application No. 95943058.8, filed Dec. 12, 1995.

Affiliated with

Also associated with

Rating

Chimeric IL-10 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Chimeric IL-10, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric IL-10 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3606053